References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:https://doi.org/10.3322/caac.21492.
- Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma. Cancer Lett. 2005;217(2):237–242. doi:https://doi.org/10.1016/j.canlet.2004.06.056.
- Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004;10(3):1057–1063. doi:https://doi.org/10.1158/1078-0432.ccr-03-0047.
- Li HC, Cao DC, Liu Y, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004;88(1):75–85. doi:https://doi.org/10.1007/s10549-004-1200-8.
- Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer – potential role in classification of patients into low risk, high risk, benign disease, and breast cancer categories. Int J Cancer. 2006;119(6):1403–1411. doi:https://doi.org/10.1002/ijc.21989.
- Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87(3-4):287–297. doi:https://doi.org/10.1016/j.biochi.2005.01.014.
- Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J. 2006;47(3):333–342. doi:https://doi.org/10.3349/ymj.2006.47.3.333.
- Böckelman C, Beilmann-Lehtonen I, Kaprio T, et al. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. BMC Cancer. 2018;18(1):679. doi:https://doi.org/10.1186/s12885-018-4589-x.
- Wang RX, Chen S, Huang L, Shao ZM. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients. BMC Cancer. 2018;18(1):909. doi:https://doi.org/10.1186/s12885-018-4822-7.
- Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 2014;14:609. doi:https://doi.org/10.1186/1471-2407-14-609.
- Li H, Qiu Z, Li F, Wang C. The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 2017;14(5):5865–5870. doi:https://doi.org/10.3892/ol.2017.6924.
- Kasurinen A, Tervahartiala T, Laitinen A, et al. High serum MMP-14 predicts worse survival in gastric cancer. PLoS One. 2018;13(12):e0208800. doi:https://doi.org/10.1371/journal.pone.0208800.
- Culhaci N, Metin K, Copcu E, Dikicioglu E. Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness. BMC Cancer. 2004;4(1):42. doi:https://doi.org/10.1186/1471-2407-4-42.
- Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol. 2003;201(4):528–534. doi:https://doi.org/10.1002/path.1466.
- Wu GJ, Bao JS, Yue ZJ, et al. Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis. J Can Res Ther. 2018;14(8):54–S59. doi:https://doi.org/10.4103/0973-1482.163761.
- Ren F, Tang R, Zhang X, et al. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0135544. doi:https://doi.org/10.1371/journal.pone.0135544.
- Wieczorek E, Galicki M, Tomasik B, et al. Expression of MMP and TIMP mRNA in peripheral blood leukocytes of patients with invasive ductal carcinoma of the breast. Int J Biol Markers. 2016;31(3):e309–e316. doi:https://doi.org/10.5301/jbm.5000203.
- González LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007;97(7):957–963. doi:https://doi.org/10.1038/sj.bjc.6603963.
- Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96(6):903–911. doi:https://doi.org/10.1038/sj.bjc.6603666.
- Yaman E, Yalcin B, Utkan G, et al. Prognostic significance of serum matrix metalloproteinase 9 (MMP-9) levels in patients with sarcomas. Int J Hematol Oncol. 2008;18(2):79–84.
- Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix mettaloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen therapy. Breast Cancer Res Treat. 2001;65(1):55–56. doi:https://doi.org/10.1023/A:1006458601568.
- Zajkowska M, Gacuta E, Kozłowska S, et al. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve. Adv Med Sci. 2019;64(1):1–8. doi:https://doi.org/10.1016/j.advms.2018.07.002.
- Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T (1–2) N0 breast carcinoma. Breast Cancer Res Treat. 2003;77(1):85–91. doi:https://doi.org/10.1023/A:1021152910976.
- Aroner SA, Rosner BA, Tamimi RM, et al. Plasma matrix metalloproteinase 2 levels and breast cancer risk. Cancer Epidemiol. 2015;39(3):321–327. doi:https://doi.org/10.1016/j.canep.2015.02.010.
- Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma. 2007;54(4):348–352.